BACKGROUND: In patients with multiple primary melanomas (MPM), mean tumor thickness tends to decrease from the first melanoma to the second melanoma, and prognosis may be improved compared with the prognosis for patients who have a single primary melanoma (SPM). In this study, the authors compared the clinicopathologic features of patients with MPM and SPM to better characterize the differences between these 2 groups and to determine whether or not there is an inherent difference in tumor aggression. METHODS: In total, 788 patients with melanoma who were enrolled prospectively in the Interdisciplinary Melanoma Cooperative Group database from 2002 to 2008 were studied. Patients with SPM and with MPM were compared with regard to clinical and primary melanoma characteristics. RESULTS: Of 788 patients with melanoma, 61 patients (7.7%) had 2 or more primary melanomas. The incidence of developing a second primary melanoma 1 year and 5 years after initial melanoma diagnosis was 4.1% and 8.7%, respectively, and most of the risk accumulated within the first year. The incidence of MPM was greater in patients aged ≥60 years than in those aged ≤60 years. The absence or presence of mitosis and other tumor characteristics did not differ significantly between patients with SPM and patients with MPM (P = .61). CONCLUSIONS: No difference was observed in the presence or absence of mitoses, a marker of tumor proliferation, in SPM and MPM. Because it has been demonstrated that the presence of mitosis is a powerful prognostic marker, the current findings suggested that the tumors behave similarly in patients with SPM and patients with MPM. The authors concluded that differences in tumor thickness and prognosis between SPM and MPM more likely are caused by factors other than tumor biology, such as increased surveillance.
BACKGROUND: In patients with multiple primary melanomas (MPM), mean tumor thickness tends to decrease from the first melanoma to the second melanoma, and prognosis may be improved compared with the prognosis for patients who have a single primary melanoma (SPM). In this study, the authors compared the clinicopathologic features of patients with MPM and SPM to better characterize the differences between these 2 groups and to determine whether or not there is an inherent difference in tumor aggression. METHODS: In total, 788 patients with melanoma who were enrolled prospectively in the Interdisciplinary Melanoma Cooperative Group database from 2002 to 2008 were studied. Patients with SPM and with MPM were compared with regard to clinical and primary melanoma characteristics. RESULTS: Of 788 patients with melanoma, 61 patients (7.7%) had 2 or more primary melanomas. The incidence of developing a second primary melanoma 1 year and 5 years after initial melanoma diagnosis was 4.1% and 8.7%, respectively, and most of the risk accumulated within the first year. The incidence of MPM was greater in patients aged ≥60 years than in those aged ≤60 years. The absence or presence of mitosis and other tumor characteristics did not differ significantly between patients with SPM and patients with MPM (P = .61). CONCLUSIONS: No difference was observed in the presence or absence of mitoses, a marker of tumor proliferation, in SPM and MPM. Because it has been demonstrated that the presence of mitosis is a powerful prognostic marker, the current findings suggested that the tumors behave similarly in patients with SPM and patients with MPM. The authors concluded that differences in tumor thickness and prognosis between SPM and MPM more likely are caused by factors other than tumor biology, such as increased surveillance.
Authors: Maris S Jones; Hitoe Torisu-Itakura; Devin C Flaherty; Hans F Schoellhammer; Jihey Lee; Myung-Shim Sim; Mark B Faries Journal: Am Surg Date: 2016-10 Impact factor: 0.688
Authors: Rodolfo David Palacios-Diaz; Blanca de Unamuno-Bustos; Carlos Abril-Pérez; Mónica Pozuelo-Ruiz; Javier Sánchez-Arraez; Ignacio Torres-Navarro; Rafael Botella-Estrada Journal: J Clin Med Date: 2022-04-22 Impact factor: 4.964
Authors: Alyssa A Wiener; Jessica R Schumacher; Jennifer M Racz; Sharon M Weber; Yaohui G Xu; Heather B Neuman Journal: Ann Surg Oncol Date: 2022-05-03 Impact factor: 4.339
Authors: Anne Kricker; Bruce K Armstrong; Chris Goumas; Nancy E Thomas; Lynn From; Klaus Busam; Peter A Kanetsky; Richard P Gallagher; Loraine D Marrett; Pamela A Groben; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Terence Dwyer; Marianne Berwick Journal: JAMA Dermatol Date: 2013-08 Impact factor: 10.282
Authors: Annie Herbert; Minjoung M Koo; Matthew E Barclay; David C Greenberg; Gary A Abel; Nick J Levell; Georgios Lyratzopoulos Journal: Melanoma Res Date: 2020-06 Impact factor: 3.199